Trial Profile
A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Registrational; Therapeutic Use
- Sponsors Molecular Insight Pharmaceuticals
- 23 Mar 2021 Results assessing impact of biomarker status on primary endpoint and objective tumor response, presented at the 103rd Annual Meeting of the Endocrine Society
- 22 Mar 2021 According to a Lantheus Holdings Media Release, data from this study was presented at the Endocrine Society 2021 Annual Meeting, ENDO 2021.
- 22 Mar 2021 Results published in the Lantheus Holdings Media Release